EVO Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -15.79% compared to Evotec SE's net margin of -227.46%. Evotec SE's return on equity of -20.84% beat BioNTech SE's return on equity of -3.91%.

Evotec SE has a consensus price target of $6.4502, signalling upside risk potential of 64.97%. On the other hand BioNTech SE has an analysts' consensus of $136.58 which suggests that it could grow by 44.1%. Given that Evotec SE has higher upside potential than BioNTech SE, analysts believe Evotec SE is more attractive than BioNTech SE.

Evotec SE has a beta of 1.715, which suggesting that the stock is 71.531% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than BioNTech SE quarterly revenues of $192.3M. Evotec SE's net income of -$33.2M is higher than BioNTech SE's net income of -$437.5M. Notably, Evotec SE's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.64x versus 7.68x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -15.79% compared to Evotec SE's net margin of 68.44%. Evotec SE's return on equity of -20.84% beat CureVac NV's return on equity of 21.3%.

Evotec SE has a consensus price target of $6.4502, signalling upside risk potential of 64.97%. On the other hand CureVac NV has an analysts' consensus of $6.24 which suggests that it could grow by 72.78%. Given that CureVac NV has higher upside potential than Evotec SE, analysts believe CureVac NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.715, which suggesting that the stock is 71.531% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are smaller than CureVac NV quarterly revenues of $543.2M. Evotec SE's net income of -$33.2M is lower than CureVac NV's net income of $371.8M. Notably, Evotec SE's price-to-earnings ratio is -- while CureVac NV's PE ratio is 4.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.64x versus 1.37x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -15.79% compared to Evotec SE's net margin of -14092.9%. Evotec SE's return on equity of -20.84% beat InflaRx NV's return on equity of -56.78%.

Evotec SE has a consensus price target of $6.4502, signalling upside risk potential of 64.97%. On the other hand InflaRx NV has an analysts' consensus of $9.56 which suggests that it could grow by 505.22%. Given that InflaRx NV has higher upside potential than Evotec SE, analysts believe InflaRx NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.715, which suggesting that the stock is 71.531% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.18%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than InflaRx NV quarterly revenues of -$450. Evotec SE's net income of -$33.2M is lower than InflaRx NV's net income of -$5.4M. Notably, Evotec SE's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.64x versus 512.31x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -15.79% compared to Evotec SE's net margin of 79.75%. Evotec SE's return on equity of -20.84% beat Immatics NV's return on equity of 3.71%.

Evotec SE has a consensus price target of $6.4502, signalling upside risk potential of 64.97%. On the other hand Immatics NV has an analysts' consensus of $15.30 which suggests that it could grow by 252.54%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.715, which suggesting that the stock is 71.531% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.706%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than Immatics NV quarterly revenues of $60M. Evotec SE's net income of -$33.2M is lower than Immatics NV's net income of $47.8M. Notably, Evotec SE's price-to-earnings ratio is -- while Immatics NV's PE ratio is 39.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.64x versus 2.81x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.